Long-Term Safety of ALKS 3831 for Schizophrenia
About this title
Read the official source — NCT02669758Researchers studied ALKS 3831, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers studied ALKS 3831, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 30 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 281
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Serbia, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT02669758
- Official title
Show the full official title
A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock, United States · Springdale, United States · Culver City, United States
28 more locations
- Garden Grove, United States
- Lemon Grove, United States
- Orange, United States
- San Diego, United States
- Miami, United States
- Chicago, United States
- St Louis, United States
- Las Vegas, United States
- Marlton, United States
- Dayton, United States
- Dallas, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Novi Iskar, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Tserova Koria, Bulgaria
- Veliko Tarnovo, Bulgaria
- Vratsa, Bulgaria
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Kneževac, Serbia
- Kharkiv, Ukraine
- Kiev, Ukraine
- Lviv, Ukraine
- Stepanovka, Ukraine
- Vinnytsia, Ukraine
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied ALKS 3831, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including ALKS 3831.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
